733 related articles for article (PubMed ID: 26756959)
1. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
[TBL] [Abstract][Full Text] [Related]
2. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).
Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A
Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
[TBL] [Abstract][Full Text] [Related]
4. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
5. Bioresorbable vascular scaffolds in coronary chronic total occlusions revascularization: safety assessment related to struts coverage and apposition in 6-month OCT follow-up.
Abellas-Sequeiros RA; Ocaranza-Sanchez R; Trillo-Nouche R; Gonzalez-Juanatey C; Gonzalez-Juanatey JR
Heart Vessels; 2017 Sep; 32(9):1077-1084. PubMed ID: 28432385
[TBL] [Abstract][Full Text] [Related]
6. Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry.
Imori Y; D'Ascenzo F; Gori T; Münzel T; Fabrizio U; Campo G; Cerrato E; Napp LC; Iannaccone M; Ghadri JR; Kazemian E; Binder RK; Jaguszewski M; Csordas A; Capasso P; Biscaglia S; Conrotto F; Varbella F; Garbo R; Gaita F; Erne P; Lüscher TF; Moretti C; Frangieh AH; Templin C
Cardiol J; 2016; 23(4):374-83. PubMed ID: 27515481
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions).
Kandzari DE; Kini AS; Karmpaliotis D; Moses JW; Tummala PE; Grantham JA; Orr C; Lombardi W; Nicholson WJ; Lembo NJ; Popma JJ; Wang J; Larracas C; Rutledge DR
JACC Cardiovasc Interv; 2015 May; 8(6):761-769. PubMed ID: 25912400
[TBL] [Abstract][Full Text] [Related]
8. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
[TBL] [Abstract][Full Text] [Related]
9. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S
Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568
[TBL] [Abstract][Full Text] [Related]
10. Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.
van Houwelingen KG; Sen H; Lam MK; Tandjung K; Löwik MM; de Man FH; Louwerenburg JH; Stoel MG; Hartmann M; Linssen GC; Doggen CJ; von Birgelen C
Catheter Cardiovasc Interv; 2015 Feb; 85(3):E76-82. PubMed ID: 25339110
[TBL] [Abstract][Full Text] [Related]
11. Comparison of outcomes after percutaneous coronary intervention for chronic total occlusion using everolimus- versus sirolimus- versus paclitaxel-eluting stents (from the Korean National Registry of Chronic Total Occlusion Intervention).
Lee MH; Lee JM; Kang SH; Yoon CH; Jang Y; Yu CW; Park HS; Lee SH; Hur SH; Kim MH; Rha SW; Gwon HC; Chae IH; Kim HS
Am J Cardiol; 2015 Jul; 116(2):195-203. PubMed ID: 26001819
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous coronary intervention for chronic total occlusion of the coronary artery with the implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry.
Lesiak M; Łanocha M; Araszkiewicz A; Siniawski A; Grygier M; Pyda M; Olasińska-Wiśniewska A; Iwanczyk S; Skorupski W; Mitkowski P; Lesiak MB; Grajek S
EuroIntervention; 2016 Jun; 12(2):e144-51. PubMed ID: 27290673
[TBL] [Abstract][Full Text] [Related]
13. Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry.
La Manna A; Miccichè E; D'Agosta G; Tensol Rodrigues Pereira G; Attizzani GF; Capranzano P; Capodanno D; Tamburino C
Int J Cardiol; 2018 Feb; 253():45-49. PubMed ID: 29137819
[TBL] [Abstract][Full Text] [Related]
14. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
[TBL] [Abstract][Full Text] [Related]
15. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study.
Ming Fam J; van Der Sijde JN; Karanasos A; Felix C; Diletti R; van Mieghem N; de Jaegere P; Zijlstra F; Jan van Geuns R; Regar E
Catheter Cardiovasc Interv; 2017 Apr; 89(5):798-810. PubMed ID: 27717119
[TBL] [Abstract][Full Text] [Related]
16. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes following bifurcation double-stenting with bioresorbable scaffolds.
Tanaka A; Latib A; Kawamoto H; Jabbour RJ; Mangieri A; Pagnesi M; Montalto C; Regazzoli D; Ancona M; Chieffo A; Carlino M; Montorfano M; Colombo A
Catheter Cardiovasc Interv; 2016 Nov; 88(6):854-862. PubMed ID: 27184769
[TBL] [Abstract][Full Text] [Related]
18. Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.
Blachutzik F; Boeder N; Wiebe J; Mattesini A; Dörr O; Most A; Bauer T; Röther J; Tröbs M; Schlundt C; Achenbach S; Hamm CW; Nef HM
Clin Res Cardiol; 2017 Apr; 106(4):271-279. PubMed ID: 27757522
[TBL] [Abstract][Full Text] [Related]
19. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: A multicenter registry.
Azzalini L; Demir OM; Gasparini GL; Grancini L; La Manna A; Ojeda S; Benincasa S; Bellini B; Poletti E; Maccagni D; Soldi M; Iannetta L; Trabattoni D; Gravina G; Hidalgo F; Giannini F; Pan M; Tamburino C; Bartorelli AL; Reimers B; Godino C; Carlino M; Colombo A
Int J Cardiol; 2018 May; 258():36-41. PubMed ID: 29426631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
